Prognosis
Arthritis Drug Seen Helping Covid-19 Patients in Small Study
- Retrospective study suggests benefit from anti-inflammatory
- Drug sold by Sweden’s Sobi as Kineret for rheumatoid arthritis
This article is for subscribers only.
A drug for rheumatoid arthritis appeared to help improve lung function in hospitalized Covid-19 patients, a positive sign for treating those with severe inflammation in their organs.
Treatment with anakinra, sold by Swedish Orphan Biovitrum AB as Kineret, was associated with a 90% survival rate and reduced respiratory symptoms, according to an observational study of 29 patients published Thursday in the Lancet Rheumatology journal.